{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:36:05Z","timestamp":1791315365659,"version":"4.3.1"},"reference-count":100,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,24]],"date-time":"2024-11-24T00:00:00Z","timestamp":1732406400000},"content-version":"am","delay-in-days":328,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004520","name":"Tokyo Institute of Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004520","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA266057"],"award-info":[{"award-number":["R01CA266057"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R21AI159323"],"award-info":[{"award-number":["R21AI159323"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["RP220232"],"award-info":[{"award-number":["RP220232"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.drudis.2023.103832","type":"journal-article","created":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T19:23:34Z","timestamp":1700076214000},"page":"103832","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Targeting SARS-CoV-2 nonstructural protein 3: Function, structure, inhibition, and perspective in drug discovery"],"prefix":"10.1016","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0189-4371","authenticated-orcid":false,"given":"Xin","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongcheng","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2023.103832_b0005","doi-asserted-by":"crossref","first-page":"eadd7197","DOI":"10.1126\/sciadv.add7197","article-title":"Nirmatrelvir-resistant SARS-CoV-2 variants with high fitness in an infectious cell culture system","volume":"8","author":"Zhou","year":"2022","journal-title":"Sci Adv"},{"key":"10.1016\/j.drudis.2023.103832_b0010","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.antiviral.2014.12.015","article-title":"The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds","volume":"115","author":"B\u00e1ez-Santos","year":"2015","journal-title":"Antiviral Res"},{"key":"10.1016\/j.drudis.2023.103832_b0015","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41586-020-2601-5","article-title":"Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity","volume":"587","author":"Shin","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2023.103832_b0020","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/s41579-021-00630-8","article-title":"Structural biology of SARS-CoV-2 and implications for therapeutic development","volume":"19","author":"Yang","year":"2021","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.drudis.2023.103832_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2021.101041","article-title":"The SARS-CoV-2 Nsp3 macrodomain reverses PARP9\/DTX3L-dependent ADP-ribosylation induced by interferon signaling","volume":"297","author":"Russo","year":"2021","journal-title":"J Biol Chem"},{"key":"10.1016\/j.drudis.2023.103832_b0030","doi-asserted-by":"crossref","first-page":"646","DOI":"10.3390\/v12060646","article-title":"A putative role of de-mono-ADP-ribosylation of STAT1 by the SARS-CoV-2 Nsp3 protein in the cytokine storm syndrome of COVID-19","volume":"12","author":"Claverie","year":"2020","journal-title":"Viruses"},{"key":"10.1016\/j.drudis.2023.103832_b0035","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2302083120","article-title":"SARS-CoV-2 Mac1 is required for IFN antagonism and efficient virus replication in cell culture and in mice","volume":"120","author":"Alhammad","year":"2023","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10.1016\/j.drudis.2023.103832_b0040","doi-asserted-by":"crossref","first-page":"964","DOI":"10.3390\/pathogens12070964","article-title":"PARPs and ADP-ribosylation in chronic inflammation: a focus on macrophages","volume":"12","author":"Santinelli-Pestana","year":"2023","journal-title":"Pathogens"},{"key":"10.1016\/j.drudis.2023.103832_b0045","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01721-16","article-title":"The conserved coronavirus macrodomain promotes virulence and suppresses the innate immune response during severe acute respiratory syndrome coronavirus infection","volume":"7","author":"Fehr","year":"2016","journal-title":"MBio"},{"key":"10.1016\/j.drudis.2023.103832_b0050","doi-asserted-by":"crossref","first-page":"7561","DOI":"10.1021\/acs.jmedchem.2c00303","article-title":"Progress and challenges in targeting the SARS-CoV-2 papain-like protease","volume":"65","author":"Tan","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2023.103832_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2022.105344","article-title":"Discovery of compounds that inhibit SARS-CoV-2 Mac1-ADP-ribose binding by high-throughput screening","volume":"203","author":"Roy","year":"2022","journal-title":"Antiviral Res"},{"key":"10.1016\/j.drudis.2023.103832_b0060","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2022.876212","article-title":"Inhibitors of SARS-CoV-2 PLpro","volume":"10","author":"Calleja","year":"2022","journal-title":"Front Chem"},{"key":"10.1016\/j.drudis.2023.103832_b0065","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.tips.2022.08.008","article-title":"Targeting SARS-CoV-2 papain-like protease in the post-vaccine era","volume":"43","author":"Ton","year":"2022","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.drudis.2023.103832_b0070","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41579-022-00713-0","article-title":"SARS-CoV-2 pathogenesis","volume":"20","author":"Lamers","year":"2022","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.drudis.2023.103832_b0075","doi-asserted-by":"crossref","first-page":"13600","DOI":"10.1128\/JVI.78.24.13600-13612.2004","article-title":"Identification of severe acute respiratory syndrome coronavirus replicase products and characterization of papain-like protease activity","volume":"78","author":"Harcourt","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.drudis.2023.103832_b0080","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/s41467-021-21060-3","article-title":"Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors","volume":"12","author":"Osipiuk","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2023.103832_b0085","first-page":"183","article-title":"Progress in anti-SARS coronavirus chemistry, biology and chemotherapy","volume":"41","author":"Ghosh","year":"2006","journal-title":"Annu Rep Med Chem"},{"key":"10.1016\/j.drudis.2023.103832_b0090","doi-asserted-by":"crossref","first-page":"32208","DOI":"10.1074\/jbc.M704870200","article-title":"Regulation of IRF-3-dependent innate immunity by the papain-like protease domain of the severe acute respiratory syndrome coronavirus","volume":"282","author":"Devaraj","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.drudis.2023.103832_b0095","doi-asserted-by":"crossref","first-page":"6689","DOI":"10.1128\/JVI.02220-08","article-title":"Severe acute respiratory syndrome coronavirus papain-like protease ubiquitin-like domain and catalytic domain regulate antagonism of IRF3 and NF-\u03baB signaling","volume":"83","author":"Frieman","year":"2009","journal-title":"J Virol"},{"key":"10.1016\/j.drudis.2023.103832_b0100","doi-asserted-by":"crossref","first-page":"5717","DOI":"10.1073\/pnas.0510851103","article-title":"Severe acute respiratory syndrome coronavirus papain-like protease: structure of a viral deubiquitinating enzyme","volume":"103","author":"Ratia","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.drudis.2023.103832_b0105","doi-asserted-by":"crossref","first-page":"eade1985","DOI":"10.1126\/scisignal.ade1985","article-title":"The substrate selectivity of papain-like proteases from human\u2013infecting coronaviruses correlates with innate immune suppression","volume":"16","author":"Xiong","year":"2023","journal-title":"Sci Signal"},{"key":"10.1016\/j.drudis.2023.103832_b0110","doi-asserted-by":"crossref","first-page":"4907","DOI":"10.1128\/JVI.00338-15","article-title":"Murine coronavirus ubiquitin-like domain is important for papain-like protease stability and viral pathogenesis","volume":"89","author":"Mielech","year":"2015","journal-title":"J Virol"},{"key":"10.1016\/j.drudis.2023.103832_b0115","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/nri1731","article-title":"Immunity by ubiquitylation: a reversible process of modification","volume":"5","author":"Liu","year":"2005","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.drudis.2023.103832_b0120","doi-asserted-by":"crossref","first-page":"e1004113","DOI":"10.1371\/journal.ppat.1004113","article-title":"Structural basis for the ubiquitin-linkage specificity and deISGylating activity of SARS-CoV papain-like protease","volume":"10","author":"Ratia","year":"2014","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.drudis.2023.103832_b0125","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1021\/acsinfecdis.0c00168","article-title":"Characterization and noncovalent inhibition of the deubiquitinase and deISGylase activity of SARS-CoV-2 papain-like protease","volume":"6","author":"Freitas","year":"2020","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.drudis.2023.103832_b0130","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1038\/s41467-023-38031-5","article-title":"Dual domain recognition determines SARS-CoV-2 PLpro selectivity for human ISG15 and K48-linked di-ubiquitin","volume":"14","author":"Wydorski","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2023.103832_b0135","doi-asserted-by":"crossref","first-page":"eabd4596","DOI":"10.1126\/sciadv.abd4596","article-title":"Activity profiling and crystal structures of inhibitor-bound SARS-CoV-2 papain-like protease: a framework for anti-COVID-19 drug design","volume":"6","author":"Rut","year":"2020","journal-title":"Sci Adv"},{"key":"10.1016\/j.drudis.2023.103832_b0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115772","article-title":"Structure and function of SARS-CoV and SARS-CoV\u20132 main proteases and their inhibition: a comprehensive review","volume":"260","author":"Li","year":"2023","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.drudis.2023.103832_b0145","doi-asserted-by":"crossref","first-page":"16119","DOI":"10.1073\/pnas.0805240105","article-title":"A noncovalent class of papain-like protease\/deubiquitinase inhibitors blocks SARS virus replication","volume":"105","author":"Ratia","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.drudis.2023.103832_b0150","doi-asserted-by":"crossref","first-page":"1067408","DOI":"10.3389\/fphar.2023.1067408","article-title":"In vitro metabolic characterization of the SARS-CoV-2 papain-like protease inhibitors GRL0617 and HY-17542","volume":"14","author":"Cho","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.drudis.2023.103832_b0155","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/s41467-020-20718-8","article-title":"The complex structure of GRL0617 and SARS-CoV-2 PLpro reveals a hot spot for antiviral drug discovery","volume":"12","author":"Fu","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2023.103832_b0160","article-title":"Discovery of novel and highly potent inhibitors of SARS CoV-2 papain-like protease through structure-based pharmacophore modeling, virtual screening, molecular docking, molecular dynamics simulations, and biological evaluation","volume":"13","author":"Tian","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.drudis.2023.103832_b0165","doi-asserted-by":"crossref","first-page":"5228","DOI":"10.1021\/jm900611t","article-title":"Structure-based design, synthesis, and biological evaluation of a series of novel and reversible inhibitors for the severe acute respiratory syndrome-coronavirus papain-like protease","volume":"52","author":"Ghosh","year":"2009","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2023.103832_b0170","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1002\/cmdc.202000548","article-title":"Structure-activity relationships of benzamides and isoindolines designed as SARS-CoV protease inhibitors effective against SARS-CoV-2","volume":"16","author":"Welker","year":"2021","journal-title":"Chemmedchem"},{"key":"10.1016\/j.drudis.2023.103832_b0175","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1021\/acs.jmedchem.1c01307","article-title":"Design of SARS-CoV-2 PLpro inhibitors for COVID-19 antiviral therapy leveraging binding cooperativity","volume":"65","author":"Shen","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2023.103832_b0180","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1021\/acscentsci.1c00519","article-title":"Discovery of SARS-CoV-2 papain-like protease inhibitors through a combination of high-throughput screening and a FlipGFP-based reporter assay","volume":"7","author":"Ma","year":"2021","journal-title":"ACS Cent Sci"},{"key":"10.1016\/j.drudis.2023.103832_b0185","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1021\/acs.jcim.2c01641","article-title":"Large-scale virtual screening for the discovery of SARS-CoV-2 papain-like protease (PLpro) non-covalent inhibitors","volume":"63","author":"Garland","year":"2023","journal-title":"J Chem Inf Model"},{"key":"10.1016\/j.drudis.2023.103832_b0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2022.105254","article-title":"Chemical screen uncovers novel structural classes of inhibitors of the papain-like protease of coronaviruses","volume":"25","author":"Jeong","year":"2022","journal-title":"Iscience"},{"key":"10.1016\/j.drudis.2023.103832_b0195","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1021\/acs.jmedchem.1c02022","article-title":"Design and evaluation of a novel peptide\u2013drug conjugate covalently targeting SARS-CoV-2 papain-like protease","volume":"65","author":"Liu","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2023.103832_b0200","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1038\/s41467-023-37254-w","article-title":"Potent and selective covalent inhibition of the papain-like protease from SARS-CoV\u20132","volume":"14","author":"Sanders","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2023.103832_b0205","doi-asserted-by":"crossref","first-page":"4968","DOI":"10.1021\/jm1004489","article-title":"Severe acute respiratory syndrome coronavirus papain-like novel protease inhibitors: design, synthesis, protein-ligand X-ray structure and biological evaluation","volume":"53","author":"Ghosh","year":"2010","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2023.103832_b0210","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1021\/jm401712t","article-title":"X-ray structural and biological evaluation of a series of potent and highly selective inhibitors of human coronavirus papain-like proteases","volume":"57","author":"B\u00e1ez-Santos","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2023.103832_b0215","doi-asserted-by":"crossref","first-page":"e106275","DOI":"10.15252\/embj.2020106275","article-title":"Mechanism and inhibition of the papain-like protease, PLpro, of SARS-CoV-2","volume":"39","author":"Klemm","year":"2020","journal-title":"EMBO J"},{"key":"10.1016\/j.drudis.2023.103832_b0220","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1021\/acsinfecdis.1c00631","article-title":"Exploring noncovalent protease inhibitors for the treatment of severe acute respiratory syndrome and severe acute respiratory syndrome-like coronaviruses","volume":"8","author":"Freitas","year":"2022","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.drudis.2023.103832_b0225","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.chembiol.2021.04.020","article-title":"Development of potent and selective inhibitors targeting the papain-like protease of SARS-CoV-2","volume":"28","author":"Shan","year":"2021","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.drudis.2023.103832_b0230","doi-asserted-by":"crossref","first-page":"5928","DOI":"10.1016\/j.bmc.2012.07.038","article-title":"Tanshinones as selective and slow-binding inhibitors for SARS-CoV cysteine proteases","volume":"20","author":"Park","year":"2012","journal-title":"Biorg Med Chem"},{"key":"10.1016\/j.drudis.2023.103832_b0235","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s13238-021-00836-9","article-title":"High-throughput screening identifies established drugs as SARS-CoV-2 PLpro inhibitors","volume":"12","author":"Zhao","year":"2021","journal-title":"Protein Cell"},{"key":"10.1016\/j.drudis.2023.103832_b0240","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1042\/BCJ20210244","article-title":"Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of Nsp3 papain-like protease","volume":"478","author":"Lim","year":"2021","journal-title":"Biochem J"},{"key":"10.1016\/j.drudis.2023.103832_b0245","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ijbiomac.2021.07.184","article-title":"Repurposing clinically approved drugs for COVID-19 treatment targeting SARS-CoV-2 papain-like protease","volume":"188","author":"Xu","year":"2021","journal-title":"Int J Biol Macromol"},{"key":"10.1016\/j.drudis.2023.103832_b0250","doi-asserted-by":"crossref","first-page":"e202100455","DOI":"10.1002\/cmdc.202100455","article-title":"Drug repurposing for the SARS-CoV-2 papain-like protease","volume":"17","author":"Cho","year":"2022","journal-title":"Chemmedchem"},{"key":"10.1016\/j.drudis.2023.103832_b0255","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1021\/acsptsci.1c00240","article-title":"Validation and invalidation of SARS-CoV-2 papain-like protease inhibitors","volume":"5","author":"Ma","year":"2022","journal-title":"ACS Pharmacol Transl Sci"},{"key":"10.1016\/j.drudis.2023.103832_b0260","doi-asserted-by":"crossref","first-page":"6553","DOI":"10.1021\/acs.jcim.2c00693","article-title":"Structure-based identification of naphthoquinones and derivatives as novel inhibitors of main protease Mpro and papain-like protease PLpro of SARS-CoV-2","volume":"62","author":"Santos","year":"2022","journal-title":"J Chem Inf Model"},{"key":"10.1016\/j.drudis.2023.103832_b0265","doi-asserted-by":"crossref","first-page":"176","DOI":"10.3390\/pharmaceutics14010176","article-title":"Drug repurposing for the identification of compounds with anti-SARS-CoV-2 capability via multiple targets","volume":"14","author":"Yu","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.drudis.2023.103832_b0270","doi-asserted-by":"crossref","first-page":"16252","DOI":"10.1021\/acs.jmedchem.2c00954","article-title":"Structure-based design of a dual-targeted covalent inhibitor against papain-like and main proteases of SARS-CoV-2","volume":"65","author":"Yu","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2023.103832_b0275","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.1016\/j.apsb.2022.07.017","article-title":"Schaftoside inhibits 3CLpro and PLpro of SARS-CoV-2 virus and regulates immune response and inflammation of host cells for the treatment of COVID-19","volume":"12","author":"Yi","year":"2022","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.drudis.2023.103832_b0280","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02577-20","article-title":"Kinetic characterization and inhibitor screening for the proteases leading to identification of drugs against SARS-CoV-2","volume":"65","author":"Kuo","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.drudis.2023.103832_b0285","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1016\/j.bmc.2013.03.027","article-title":"Geranylated flavonoids displaying SARS-CoV papain-like protease inhibition from the fruits of Paulownia tomentosa","volume":"21","author":"Cho","year":"2013","journal-title":"Biorg Med Chem"},{"key":"10.1016\/j.drudis.2023.103832_b0290","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3109\/14756366.2012.753591","article-title":"Phenolic phytochemical displaying SARS-CoV papain-like protease inhibition from the seeds of Psoralea corylifolia","volume":"29","author":"Kim","year":"2014","journal-title":"J Enzyme Inhib Med Chem"},{"key":"10.1016\/j.drudis.2023.103832_b0295","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1080\/14756366.2016.1265519","article-title":"Evaluation of polyphenols from Broussonetia papyrifera as coronavirus protease inhibitors","volume":"32","author":"Park","year":"2017","journal-title":"J Enzyme Inhib Med Chem"},{"key":"10.1016\/j.drudis.2023.103832_b0300","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3109\/14756366.2014.1003215","article-title":"Chalcones isolated from Angelica keiskei inhibit cysteine proteases of SARS-CoV","volume":"31","author":"Park","year":"2016","journal-title":"J Enzyme Inhib Med Chem"},{"key":"10.1016\/j.drudis.2023.103832_b0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.phytochem.2021.112984","article-title":"Natural biflavones are potent inhibitors against SARS-CoV-2 papain-like protease","volume":"193","author":"Li","year":"2022","journal-title":"Phytochem"},{"key":"10.1016\/j.drudis.2023.103832_b0310","doi-asserted-by":"crossref","first-page":"9904","DOI":"10.1039\/D0SC02646H","article-title":"Multi-targeting of functional cysteines in multiple conserved SARS-CoV-2 domains by clinically safe Zn-ejectors","volume":"11","author":"Sargsyan","year":"2020","journal-title":"Chem Sci"},{"key":"10.1016\/j.drudis.2023.103832_b0315","doi-asserted-by":"crossref","unstructured":"W\u0119glarz\u2013Tomczak E, Tomczak JM, Talma M, Brul S. Ebselen as a highly active inhibitor of PLProCoV2. BioRxiv. Published online May 17, 2020. https:\/\/doi.org\/10.1101\/2020.05.17.100768.","DOI":"10.1101\/2020.05.17.100768"},{"key":"10.1016\/j.drudis.2023.103832_b0320","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1038\/s41467-021-23313-7","article-title":"Inhibition mechanism of SARS-CoV-2 main protease by ebselen and its derivatives","volume":"12","author":"Amporndanai","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2023.103832_b0325","doi-asserted-by":"crossref","unstructured":"Zmudzinski M, et al. Ebselen derivatives are very potent dual inhibitors of SARS-CoV-2 proteases\u2013PLpro and Mpro in in vitro studies. BioRxiv. Published online August 30, 2023. https:\/\/doi.org\/10.1101\/2020.08.30.273979.","DOI":"10.1101\/2020.08.30.273979"},{"key":"10.1016\/j.drudis.2023.103832_b0330","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1038\/s41598-021-83229-6","article-title":"Identification of ebselen and its analogues as potent covalent inhibitors of papain-like protease from SARS-CoV-2","volume":"11","author":"Weglarz-Tomczak","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.drudis.2023.103832_b0335","doi-asserted-by":"crossref","first-page":"e28479","DOI":"10.1371\/journal.pone.0028479","article-title":"Yeast based small molecule screen for inhibitors of SARS-CoV","volume":"6","author":"Frieman","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.drudis.2023.103832_b0340","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.antiviral.2017.12.015","article-title":"Disulfiram can inhibit MERS and SARS coronavirus papain-like proteases via different modes","volume":"150","author":"Lin","year":"2018","journal-title":"Antiviral Res"},{"key":"10.1016\/j.drudis.2023.103832_b0345","doi-asserted-by":"crossref","first-page":"744","DOI":"10.3390\/ph15060744","article-title":"Discovery of triple inhibitors of both SARS-CoV-2 proteases and human cathepsin L","volume":"15","author":"Meewan","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.drudis.2023.103832_b0350","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1016\/j.bcp.2008.01.005","article-title":"Thiopurine analogues inhibit papain-like protease of severe acute respiratory syndrome coronavirus","volume":"75","author":"Chou","year":"2008","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.drudis.2023.103832_b0355","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.103213","article-title":"6-Thioguanine blocks SARS-CoV-2 replication by inhibition of PLpro protease activities","volume":"24","author":"Swaim","year":"2021","journal-title":"iScience"},{"key":"10.1016\/j.drudis.2023.103832_b0360","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113863","article-title":"Identification of a dual acting SARS-CoV-2 proteases inhibitor through in silico design and step-by-step biological characterization","volume":"226","author":"Di Sarno","year":"2021","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.drudis.2023.103832_b0365","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115380","article-title":"Discovery of novel papain-like protease inhibitors for potential treatment of COVID-19","volume":"254","author":"Hersi","year":"2023","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.drudis.2023.103832_b0370","doi-asserted-by":"crossref","unstructured":"Shen Z, et al. Potent, novel SARS-CoV-2 PLpro inhibitors block viral replication in monkey and human cell cultures. BioRxiv. Published online February 15, 2021. https:\/\/doi.org\/10.1101\/2021.02.13.431008.","DOI":"10.1101\/2021.02.13.431008"},{"key":"10.1016\/j.drudis.2023.103832_b0375","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/cbdd.14115","article-title":"Hydrogen bonding penalty used for virtual screening to discover potent inhibitors for Papain-Like cysteine proteases of SARS-CoV-2","volume":"100","author":"Zhao","year":"2022","journal-title":"Chem Biol Drug Des"},{"key":"10.1016\/j.drudis.2023.103832_b0380","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2023.124772","article-title":"Development of 2-chloroquinoline based heterocyclic frameworks as dual inhibitors of SARS-CoV-2 MPro and PLPro","volume":"242","author":"Kattula","year":"2023","journal-title":"Int J Biol Macromol"},{"key":"10.1016\/j.drudis.2023.103832_b0385","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.chembiol.2021.11.006","article-title":"Acriflavine, a clinically approved drug, inhibits SARS-CoV-2 and other betacoronaviruses","volume":"29","author":"Napolitano","year":"2022","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.drudis.2023.103832_b0390","doi-asserted-by":"crossref","unstructured":"Rut W, et al. Activity profiling and structures of inhibitor-bound SARS-CoV-2-PLpro protease provides a framework for anti-COVID-19 drug design. bioRxiv. Published online May 15, 2020. https:\/\/doi.org\/10.1101\/2020.04.29.068890.","DOI":"10.1101\/2020.04.29.068890"},{"key":"10.1016\/j.drudis.2023.103832_b0395","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115272","article-title":"Repurposing 1, 2, 4-oxadiazoles as SARS-CoV-2 PLpro inhibitors and investigation of their possible viral entry blockade potential","volume":"252","author":"Ayoup","year":"2023","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.drudis.2023.103832_b0400","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2021.128099","article-title":"Promising anti-SARS-CoV-2 drugs by effective dual targeting against the viral and host proteases","volume":"43","author":"Elseginy","year":"2021","journal-title":"Biorg Med Chem Lett"},{"key":"10.1016\/j.drudis.2023.103832_b0405","first-page":"17","article-title":"High-throughput screening of SARS-CoV-2 main and papain-like protease inhibitors","volume":"14","author":"Zang","year":"2023","journal-title":"Protein Cell"},{"key":"10.1016\/j.drudis.2023.103832_b0410","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1248\/bpb.b12-00623","article-title":"Diarylheptanoids from Alnus japonica inhibit papain-like protease of severe acute respiratory syndrome coronavirus","volume":"35","author":"Park","year":"2012","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.drudis.2023.103832_b0415","doi-asserted-by":"crossref","first-page":"e1007756","DOI":"10.1371\/journal.ppat.1007756","article-title":"The coronavirus macrodomain is required to prevent PARP-mediated inhibition of virus replication and enhancement of IFN expression","volume":"15","author":"Grunewald","year":"2019","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.drudis.2023.103832_b0420","doi-asserted-by":"crossref","first-page":"12849","DOI":"10.1038\/ncomms12849","article-title":"PARP9 and PARP14 cross-regulate macrophage activation via STAT1 ADP-ribosylation","volume":"7","author":"Iwata","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2023.103832_b0425","doi-asserted-by":"crossref","first-page":"94","DOI":"10.3390\/pathogens11010094","article-title":"The conserved macrodomain is a potential therapeutic target for coronaviruses and alphaviruses","volume":"11","author":"Leung","year":"2022","journal-title":"Pathogens"},{"key":"10.1016\/j.drudis.2023.103832_b0430","doi-asserted-by":"crossref","DOI":"10.1098\/rsob.200237","article-title":"Viral macrodomains: a structural and evolutionary assessment of the pharmacological potential","volume":"10","author":"Rack","year":"2020","journal-title":"Open Biol"},{"key":"10.1016\/j.drudis.2023.103832_b0435","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1016\/j.drudis.2021.05.007","article-title":"The search for inhibitors of macrodomains for targeting the readers and erasers of mono-ADP-ribosylation","volume":"26","author":"Fu","year":"2021","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.drudis.2023.103832_b0440","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41392-022-00884-5","article-title":"Structural biology of SARS-CoV-2: open the door for novel therapies","volume":"7","author":"Yan","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.drudis.2023.103832_b0445","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1021\/acs.biochem.0c00309","article-title":"Molecular basis for ADP-ribose binding to the Mac1 domain of SARS-CoV-2 nsp3","volume":"59","author":"Frick","year":"2020","journal-title":"Biochem"},{"key":"10.1016\/j.drudis.2023.103832_b0450","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1107\/S2052252520009653","article-title":"Crystal structures of SARS-CoV-2 ADP-ribose phosphatase: from the apo form to ligand complexes","volume":"7","author":"Michalska","year":"2020","journal-title":"IUCrJ"},{"key":"10.1016\/j.drudis.2023.103832_b0455","doi-asserted-by":"crossref","first-page":"8478","DOI":"10.1128\/JVI.00705-16","article-title":"Viral macro domains reverse protein ADP-ribosylation","volume":"90","author":"Li","year":"2016","journal-title":"J Virol"},{"key":"10.1016\/j.drudis.2023.103832_b0460","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/nsmb.2523","article-title":"A family of macrodomain proteins reverses cellular mono-ADP-ribosylation","volume":"20","author":"Jankevicius","year":"2013","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.drudis.2023.103832_b0465","doi-asserted-by":"crossref","first-page":"eabf8711","DOI":"10.1126\/sciadv.abf8711","article-title":"Fragment binding to the Nsp3 macrodomain of SARS-CoV-2 identified through crystallographic screening and computational docking","volume":"7","author":"Schuller","year":"2021","journal-title":"Sci Adv"},{"key":"10.1016\/j.drudis.2023.103832_b0470","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2212931120","article-title":"Iterative computational design and crystallographic screening identifies potent inhibitors targeting the Nsp3 macrodomain of SARS-CoV\u20132","volume":"120","author":"Gahbauer","year":"2023","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.drudis.2023.103832_b0475","doi-asserted-by":"crossref","first-page":"324","DOI":"10.3390\/pathogens12020324","article-title":"Discovery and development strategies for SARS-CoV-2 NSP3 macrodomain inhibitors","volume":"12","author":"Schuller","year":"2023","journal-title":"Pathogens"},{"key":"10.1016\/j.drudis.2023.103832_b0480","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2022.116788","article-title":"Design, synthesis and evaluation of inhibitors of the SARS-CoV-2 nsp3 macrodomain","volume":"67","author":"Sherrill","year":"2022","journal-title":"Biorg Med Chem"},{"key":"10.1016\/j.drudis.2023.103832_b0485","doi-asserted-by":"crossref","first-page":"e0253364","DOI":"10.1371\/journal.pone.0253364","article-title":"Biochemical characterization of protease activity of Nsp3 from SARS-CoV-2 and its inhibition by nanobodies","volume":"16","author":"Armstrong","year":"2021","journal-title":"PLoS ONE"},{"key":"10.1016\/j.drudis.2023.103832_b0490","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-020-00885-3","article-title":"Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy","volume":"13","author":"Li","year":"2020","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.drudis.2023.103832_b0495","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1038\/s41467-019-11429-w","article-title":"Small molecule degraders of the hepatitis C virus protease reduce susceptibility to resistance mutations","volume":"10","author":"de Wispelaere","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2023.103832_b0500","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellin.2022.100030","article-title":"Discovery of oseltamivir-based novel PROTACs as degraders targeting neuraminidase to combat H1N1 influenza virus","volume":"1","author":"Xu","year":"2022","journal-title":"Cell Insight"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644623003483?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644623003483?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T13:09:03Z","timestamp":1761224943000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644623003483"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":100,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S1359644623003483"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2023.103832","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting SARS-CoV-2 nonstructural protein 3: Function, structure, inhibition, and perspective in drug discovery","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2023.103832","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103832"}}